keyword
https://read.qxmd.com/read/38333300/suspected-nut-carcinoma-progressing-on-pembrolizumab-carboplatin-and-paclitaxel-as-first-line-treatment-a-case-report
#21
Ahmed Badran, Saad Salman Ali, Tarek Ziad Arabi, Abdulaziz Mohammed Alaklabi, Hytham Mubarak Abdalla, Shamayel Mohammed, Belal Nedal Sabbah, Mahmoud A Elshenawy, Jean Paul Atallah
INTRODUCTION AND IMPORTANCE: NUT carcinoma of the thorax is an extremely rare neoplasm characterized by a translocation between the NUT M1 gene and members of the bromodomain genetic family. Due to the rarity of the neoplasm, standardized treatment guidelines have not yet been established. Several chemotherapeutic agents have been used with limited success, due to the rapid development of resistance to treatment. Pembrolizumab, an anti-programmed-death-1 antibody, has become increasingly used in non-small-cell lung carcinomas...
February 2024: Annals of Medicine and Surgery
https://read.qxmd.com/read/38327131/high-flt3-expression-increases-immune-cell-infiltration-in-the-tumor-microenvironment-and-correlates-with-prolonged-disease-free-survival-in-patients-with-non-small-cell-lung-cancer
#22
JOURNAL ARTICLE
Łukasz Kuncman, Magdalena Orzechowska, Tomasz Milecki, Jakub Kucharz, Jacek Fijuth
Most of the currently used cancer immunotherapies inhibit the programmed cell death protein 1 (PD1)-programmed cell death 1 ligand 1 (PDL1) axis of T-cells. However, dendritic cells (DCs) controlled by natural killer (NK) cells via the FMS-related tyrosine kinase 3 (FLT3) axis are necessary for activation of T-cells. The aim of the study was to evaluate FLT3 as a prognostic factor and determine its role in immune infiltration (with emphasis on NK cells and DCs). Using The Cancer Genome Atlas (TCGA) database, we performed bioinformatic analysis of the gene expression datasets of 501 lung squamous cell carcinoma (LUSC) and 515 lung adenocarcinoma (LUAD) patient who had corresponding clinical data [analysis was performed in R (version 4...
February 7, 2024: Molecular Oncology
https://read.qxmd.com/read/38327102/an-algorithm-based-on-immunotherapy-discontinuation-and-liver-biopsy-spares-corticosteroids-in-two-thirds-of-cases-of-severe-checkpoint-inhibitor-induced-liver-injury
#23
JOURNAL ARTICLE
Mar Riveiro-Barciela, Ana Barreira-Díaz, María-Teresa Salcedo, Ana Callejo-Pérez, Eva Muñoz-Couselo, Patricia Iranzo, Carolina Ortiz-Velez, Susana Cedrés, Nely Díaz-Mejía, Juan Carlos Ruiz-Cobo, Rafael Morales, Juan Aguilar-Company, Ester Zamora, Mafalda Oliveira, María-Teresa Sanz-Martínez, Lluis Viladomiu, Mónica Martínez-Gallo, Enriqueta Felip, María Buti
BACKGROUND: There are few data on corticosteroids (CS)-sparing strategies for checkpoint inhibitor (ICI)-induced liver injury (ChILI). AIM: We aimed to assess the performance of a 2-step algorithm for severe ChILI, based on ICI temporary discontinuation (step-1) and, if lack of biochemical improvement, CS based on the degree of necroinflammation at biopsy (step-2). METHODS: Prospective study that included all subjects with grade 3/4 ChILI...
February 7, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38316697/il-32-production-from-lung-adenocarcinoma-cells-is-potentially-involved-in-immunosuppressive-microenvironment
#24
JOURNAL ARTICLE
Shukang Zhao, Lianbo Li, Yoshihiro Komohara, Eri Matsubara, Yusuke Shinchi, Ahmad Adawy, Hiromu Yano, Cheng Pan, Yukio Fujiwara, Koei Ikeda, Shinya Suzu, Taizo Hibi, Makoto Suzuki
Interleukin 32 (IL-32) is a proinflammatory cytokine secreted from several kinds of cancer cells. In the present study, we investigated the significance of IL-32 in lung adenocarcinoma by immunohistochemistry and bioinformatics analysis. IL-32 was positive in cancer cells of 21 cases (9.2%) of total 228 cases. Increased IL-32 gene expression was linked to worse clinical course in TCGA analysis, however, IL-32 expression in immunohistochemistry was not associated to clinical course in our cohort. It was also found that high IL-32 expression was seen in cases with increased lymphocyte infiltration...
February 6, 2024: Medical Molecular Morphology
https://read.qxmd.com/read/38280521/gut-microbiota-and-clinical-response-to-immune-checkpoint-inhibitor-therapy-in-patients-with-advanced-cancer
#25
JOURNAL ARTICLE
John Wen-Cheng Chang, Jia-Juan Hsieh, Chih-Yu Tsai, Horng-Yih Chiu, Yu-Feng Lin, Chiao-En Wu, Yung-Chi Shen, Ming-Mo Hou, Chieh-Ying Chang, Jian-An Chen, Chyi-Liang Chen, Cheng-Tang Chiu, Yuan-Ming Yeh, Cheng-Hsun Chiu
BACKGROUND: There is currently no well-accepted consensus on the association between gut microbiota and the response to treatment of immune checkpoint inhibitors (ICIs) in patients with advanced cancer. METHODS: Fecal samples were collected before ICI treatment. Gut microbiota was analyzed using 16 S ribosomal RNA sequencing. We investigated the relationship between the α-diversity of fecal microbiota and patients' clinical outcomes. Microbiota profiles from patients and healthy controls were determined...
January 25, 2024: Biomedical Journal
https://read.qxmd.com/read/38269509/amplifying-t-cell-mediated-antitumor-immune-responses%C3%A2-in-nonsmall-cell-lung-cancer-through-photodynamic-therapy-and-anti-pd1
#26
JOURNAL ARTICLE
Beilei Gong, Liping Wang, Han Zhang, Qingkai Wang, Wei Li
Photodynamic therapy (PDT) is nowadays widely employed in cancer treatment. We sought to assess the efficacy of combining PDT with anti-programmed cell death protein 1 (PD1) and to investigate the associated mechanisms in nonsmall cell lung cancer (NSCLC). We established a xenograft tumor model in C57BL/6J mice using Lewis lung carcinoma (LLC) cells, recorded tumor growth, and quantified reactive oxygen species (ROS) levels using a ROS detection kit. Pathological changes were assessed through H&E staining, while immunofluorescence (IF) was used to determine the expression of CD8 and Foxp3...
January 2024: Cell Biochemistry and Function
https://read.qxmd.com/read/38265267/ezh2-inhibition-promotes-tumor-immunogenicity-in-lung-squamous-cell-carcinomas
#27
JOURNAL ARTICLE
Tanner J DuCote, Xiulong Song, Kassandra J Naughton, Fan Chen, Daniel R Plaugher, Avery R Childress, Abigail R Gellert, Erika M Skaggs, Xufeng Qu, Jinze Liu, Jinpeng Liu, Fei Li, Kwok-Kin Wong, Christine F Brainson
UNLABELLED: Two important factors that contribute to resistance to immune checkpoint inhibitors (ICI) are an immune-suppressive microenvironment and limited antigen presentation by tumor cells. In this study, we examine whether inhibition of the methyltransferase enhancer of zeste 2 (EZH2) can increase ICI response in lung squamous cell carcinomas (LSCC). Our in vitro experiments using two-dimensional human cancer cell lines as well as three-dimensional murine and patient-derived organoids treated with two inhibitors of the EZH2 plus IFNγ showed that EZH2 inhibition leads to expression of both MHC class I and II (MHCI/II) expression at both the mRNA and protein levels...
February 13, 2024: Cancer Res Commun
https://read.qxmd.com/read/38261733/the-integration-of-multi-omics-analysis-and-machine-learning-for-the-identification-of-prognostic-assessment-and-immunotherapy-efficacy-through-aging-associated-genes-in-lung-cancer
#28
JOURNAL ARTICLE
Wei Lu, Yun Zhou, Ruixuan Zhao, Qiushi Liu, Wei Yang, Tianyi Zhu
BACKGROUND: Recent years revealed key molecules in lung cancer research, yet their exact roles in disease onset and progression remain uncertain. Lung cancer's heterogeneity complicates prognosis prediction. This study integrates pivotal molecules to evaluate patient prognosis and immunotherapy efficacy. METHODS: The WGCNA algorithm identified module genes linked to immunity. The Lasso-Cox method built a prognostic model for outcome prediction. GO and KEGG analyses explored gene pathways...
January 22, 2024: Aging
https://read.qxmd.com/read/38241355/genome-wide-analyses-reveal-the-contribution-of-somatic-variants-to-the-immune-landscape-of-multiple-cancer-types
#29
JOURNAL ARTICLE
Wenjian Bi, Zhiyu Xu, Feng Liu, Zhi Xie, Hao Liu, Xiaotian Zhu, Wenge Zhong, Peipei Zhang, Xing Tang
It has been well established that cancer cells can evade immune surveillance by mutating themselves. Understanding genetic alterations in cancer cells that contribute to immune regulation could lead to better immunotherapy patient stratification and identification of novel immune-oncology (IO) targets. In this report, we describe our effort of genome-wide association analyses across 22 TCGA cancer types to explore the associations between genetic alterations in cancer cells and 76 immune traits. Results showed that the tumor microenvironment (TME) is shaped by different gene mutations in different cancer types...
January 19, 2024: PLoS Genetics
https://read.qxmd.com/read/38226313/inflammatory-response-signature-score-model-for-predicting-immunotherapy-response-and-pan-cancer-prognosis
#30
JOURNAL ARTICLE
Shuzhao Chen, Mayan Huang, Limei Zhang, Qianqian Huang, Yun Wang, Yang Liang
BACKGROUND: Inflammatory responses influence the outcome of immunotherapy and tumorigenesis by modulating host immunity. However, systematic inflammatory response assessment models for predicting cancer immunotherapy (CIT) responses and survival across human cancers remain unexplored. Here, we investigated an inflammatory response score model to predict CIT responses and patient survival in a pan-cancer analysis. METHODS: We retrieved 12 CIT response gene expression datasets from the Gene Expression Omnibus database (GSE78220, GSE19423, GSE100797, GSE126044, GSE35640, GSE67501, GSE115821 and GSE168204), Tumor Immune Dysfunction and Exclusion database (PRJEB23709, PRJEB25780 and phs000452...
December 2024: Computational and Structural Biotechnology Journal
https://read.qxmd.com/read/38207230/genomic-and-immunophenotypic-landscape-of-acquired-resistance-to-pd-l-1-blockade-in-non-small-cell-lung-cancer
#31
JOURNAL ARTICLE
Biagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, Navin R Mahadevan, Jia-Ren Lin, Joao V Alessi, Alexander Chowdhury, Yvonne Y Li, Xinan Wang, Liam Spurr, Federica Pecci, Alessandro Di Federico, Deepti Venkatraman, Adriana P Barrichello, Malini Gandhi, Victor R Vaz, Andy J Pangilinan, Danielle Haradon, Elinton Lee, Hersh Gupta, Kathleen L Pfaff, Emma L Welsh, Mizuki Nishino, Andrew D Cherniack, Bruce E Johnson, Jason L Weirather, Ian D Dryg, Scott J Rodig, Lynette M Sholl, Peter Sorger, Sandro Santagata, Renato Umeton, Mark M Awad
PURPOSE: Although immune checkpoint inhibitors (ICI) have extended survival in patients with non-small-cell lung cancer (NSCLC), acquired resistance (AR) to ICI frequently develops after an initial benefit. However, the mechanisms of AR to ICI in NSCLC are largely unknown. METHODS: Comprehensive tumor genomic profiling, machine learning-based assessment of tumor-infiltrating lymphocytes, multiplexed immunofluorescence, and/or HLA-I immunohistochemistry (IHC) were performed on matched pre- and post-ICI tumor biopsies from patients with NSCLC treated with ICI at the Dana-Farber Cancer Institute who developed AR to ICI...
January 11, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38181798/interferon-stimulated-neutrophils-as-a-predictor-of-immunotherapy-response
#32
JOURNAL ARTICLE
Madeleine Benguigui, Tim J Cooper, Prajakta Kalkar, Sagie Schif-Zuck, Ruth Halaban, Antonella Bacchiocchi, Iris Kamer, Abhilash Deo, Bar Manobla, Rotem Menachem, Jozafina Haj-Shomaly, Avital Vorontsova, Ziv Raviv, Chen Buxbaum, Petros Christopoulos, Jair Bar, Michal Lotem, Mario Sznol, Amiram Ariel, Shai S Shen-Orr, Yuval Shaked
Despite the remarkable success of anti-cancer immunotherapy, its effectiveness remains confined to a subset of patients-emphasizing the importance of predictive biomarkers in clinical decision-making and further mechanistic understanding of treatment response. Current biomarkers, however, lack the power required to accurately stratify patients. Here, we identify interferon-stimulated, Ly6Ehi neutrophils as a blood-borne biomarker of anti-PD1 response in mice at baseline. Ly6Ehi neutrophils are induced by tumor-intrinsic activation of the STING (stimulator of interferon genes) signaling pathway and possess the ability to directly sensitize otherwise non-responsive tumors to anti-PD1 therapy, in part through IL12b-dependent activation of cytotoxic T cells...
February 12, 2024: Cancer Cell
https://read.qxmd.com/read/38170412/population-based-high-dimensional-analyses-identify-multiple-intrinsic-characters-for-cancer-vaccines-against-lung-squamous-cell-carcinoma
#33
JOURNAL ARTICLE
Longjin Zeng, Lingchen Li, Xingyun Liao, Lincheng Zhang, Chenrui Yin, Xiewan Chen, Jianguo Sun
In lung squamous cell carcinoma (LUSC), current cancer vaccines show promising effects, despite a lack of benefit for a large number of patients. We first identified the tumor antigens into shared and private antigens, and determined the population by clustering analysis in public datasets. For vaccine development, The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC) were collected. WGCNA method was furthermore applied to construct a consensus gene co-expression network based on TCGA and CPTAC datasets...
January 3, 2024: Medical Oncology
https://read.qxmd.com/read/38170160/a-phase-2-multicenter-open-label-study-of-anti-lag-3-ieramilimab-in-combination-with-anti-pd-1-spartalizumab-in-patients-with-advanced-solid-malignancies
#34
MULTICENTER STUDY
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S Hong, Lillian L Siu, Miguel Martin, Michela Maur, Rina Hui, Ross A Soo, Joanne Chiu, Tian Zhang, Brigette Ma, Chrisann Kyi, Daniel Sw Tan, Philippe A Cassier, John Sarantopoulos, Andrew Weickhardt, Richard D Carvajal, Jennifer Spratlin, Taito Esaki, Fréderic Rolland, Wallace Akerley, Barbara Deschler-Baier, Lawrence Rispoli, Tanay S Samant, Niladri Roy Chowdhury, Daniel Gusenleitner, Eunice L Kwak, Vasileios Askoxylakis, Filippo De Braud
Ieramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the efficacy and safety of combination treatment in patients with selected advanced (locally advanced or metastatic) solid malignancies. Eligible patients with non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), mesothelioma, and triple-negative breast cancer (TNBC) were grouped depending on prior anti-PD-1/L1 therapy (anti-PD-1/L1 naive or anti-PD-1/L1 pretreated)...
2024: Oncoimmunology
https://read.qxmd.com/read/38160516/ct-based-subregional-radiomics-using-hand-crafted-and-deep-learning-features-for-prediction-of-therapeutic-response-to-anti-pd1-therapy-in-nsclc
#35
JOURNAL ARTICLE
Yue Hu, Tao Jiang, Huan Wang, Jiangdian Song, Zhiguang Yang, Yan Wang, Juan Su, Meiqi Jin, Shijie Chang, Kexue Deng, Wenyan Jiang
PURPOSE: To develop and externally validate subregional radiomics for predicting therapeutic response to anti-PD1 therapy in non-small-cell lung cancer (NSCLC). METHODS: Sixty-six patients from center 1 served as training and internal validation cohorts. Thirty patients from center 2 and thirty patients from center 3 served as external validation 1 and external validation 2 cohorts, respectively. The lesions identified on CT scans were subdivided into two phenotypically consistent subregions by automatic clustering on the patient-level and population-level (denoted as marginal S1 and inner S2)...
December 30, 2023: Physica Medica: PM
https://read.qxmd.com/read/38072173/kras-g12c-mutant-driven-non-small-cell-lung-cancer-nsclc
#36
REVIEW
Rafael Rosell, Jordi Codony-Servat, Jessica González, Mariacarmela Santarpia, Anisha Jain, Chandan Shivamallu, Yu Wang, Ana Giménez-Capitán, Miguel A Molina-Vila, Jonas Nilsson, María González-Cao
KRAS G12C mutations in non-small cell lung cancer (NSCLC) partially respond to KRAS G12C covalent inhibitors. However, early adaptive resistance occurs due to rewiring of signaling pathways, activating receptor tyrosine kinases, primarily EGFR, but also MET and ligands. Evidence indicates that treatment with KRAS G12C inhibitors (sotorasib) triggers the MRAS:SHOC2:PP1C trimeric complex. Activation of MRAS occurs from alterations in the Scribble and Hippo-dependent pathways, leading to YAP activation. Other mechanisms that involve STAT3 signaling are intertwined with the activation of MRAS...
December 9, 2023: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38048058/trop2-is-associated-with-primary-resistance-to-immune-checkpoint-inhibition-in-patients-with-advanced-non-small-cell-lung-cancer
#37
JOURNAL ARTICLE
Alban Bessede, Florent Peyraud, Benjamin Besse, Sophie Cousin, Mathilde Cabart, François Chomy, Christophe Rey, Oren Lara, Ophélie Odin, Imane Nafia, Lucile Vanhersecke, Fabrice Barlesi, Jean-Philippe Guégan, Antoine Italiano
PURPOSE: Mechanisms of primary resistance to inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis in non-small cell lung cancer (NSCLC) are still poorly understood. While some studies suggest TROP2's involvement in modulating tumor cell resistance to therapeutic drugs, its specific role in the context of PD1/PD-L1 axis blockade is not definitively established. EXPERIMENTAL DESIGN: We performed high-throughput analysis of transcriptomic data from 891 NSCLC tumors from patients treated with either the PD-L1 inhibitor atezolizumab or chemotherapy in two large randomized clinical trials...
December 1, 2023: Clinical Cancer Research
https://read.qxmd.com/read/38023206/genomic-alterations-associated-with-pseudoprogression-and-hyperprogressive-disease-during-anti-pd1-treatment-for-advanced-non-small-cell-lung-cancer
#38
JOURNAL ARTICLE
Rui Zhou, Fan Tong, Yongchang Zhang, Ruigang Zhang, Yawen Bin, Sheng Zhang, Nong Yang, Xiaorong Dong
INTRODUCTION: This study aimed to elucidate the relationship between dynamic genomic mutation alteration and pseudoprogression (PsPD)/hyperprogressive disease (HPD) in immunotherapy-treated advanced non-small-cell lung cancer (NSCLC), to provide clinical evidence for identifying and distinguishing between PsPD and HPD. METHOD: Patients with advanced NSCLC who were treated with anti-PD1 were enrolled. Whole blood was collected at baseline and post image progression...
2023: Frontiers in Oncology
https://read.qxmd.com/read/38008641/influence-of-tumor-cavitation-on-assessing-the-clinical-benefit-of-anti-pd1-or-pd-l1-inhibitors-in-advanced-lung-squamous-cell-carcinoma
#39
JOURNAL ARTICLE
Qin Chen, Jing Wang, Xinyue Wang, Yan Yin, Xuan Wang, Zhenchun Song, Bin Xing, Yajing Li, Jingjing Zhang, Jianwen Qin, Richeng Jiang
PURPOSE: A considerable portion of lung squamous cell cancer (LUSC) displays radiographic signs of cavitation. The cavitation of lesions is not accounted for in the prevailing Evaluation Criteria of Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or iRECIST in lung cancer. We hypothesized that cavitation might alter response assessment in these patients. PATIENTS AND METHODS: We performed a retrospective radiologic review of 785 patients with stage IV LUSC treated with PD-1/PD-L1 antibody combined with platinum-based doublet chemotherapy...
January 2024: Clinical Lung Cancer
https://read.qxmd.com/read/38007784/study-on-targeted-drugs-for-non-small-cell-nsclc-with-pd-1pd-l1-signaling-pathway
#40
JOURNAL ARTICLE
Xinran Cao
OBJECTIVE: To study the biological function and clinical significance of PD-1/PD-L1 representation in non-small cell lung cancer (NSCLC), and the representation and correlation of PD-1/PD-L1 and epidermal growth factor receptor (EGFR) in NSCLC. METHODS: The pathological specimens and clinical data of 108 patients with NSCLC were collected. The representation of PD-1/PD-L1 was detected by immunohistochemistry, and the representation of EGFR was detected by PCR. Logistic regression analysis was used to assess the correlation between PD-1/PD-L1 and EGFR...
November 23, 2023: Studies in Health Technology and Informatics
keyword
keyword
108598
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.